Ezio Ghigo

Q: What Schools Are Affiliated With Ezio Ghigo

Ezio Ghigo is affiliated with the following schools: University of Milan, University of Turin

Ezio Ghigo's AcademicInfluence.com Rankings

Ezio Ghigo

Physics

#4464

World Rank

#6134

Historical Rank

Particle Physics

#187

World Rank

#200

Historical Rank

physics Degrees

Download Badge

Physics

Ezio Ghigo's Degrees

PhD Physics University of Turin
Masters Physics University of Turin
Bachelors Physics University of Turin

Why Is Ezio Ghigo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ezio Ghigo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. (2004) (1194)
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. (2001) (732)
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT (2002) (729)
A consensus on criteria for cure of acromegaly. (2010) (712)
Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. (1998) (675)
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. (2001) (567)
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. (2007) (482)
Growth hormone secretagogue binding sites in peripheral human tissues. (2000) (441)
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans (2000) (405)
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. (2002) (402)
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. (2002) (374)
Ghrelin (2015) (371)
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. (2004) (365)
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. (2001) (349)
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. (2005) (343)
Changes in Weight and Nutritional Habits in Adults with Obesity during the “Lockdown” Period Caused by the COVID-19 Virus Emergency (2020) (338)
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury (2004) (321)
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. (2005) (308)
Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. (2007) (301)
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. (2005) (299)
Neuroendocrine control of growth hormone secretion. (1999) (297)
Extracellular vesicles as an emerging mechanism of cell-to-cell communication (2012) (297)
Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. (1996) (288)
Ghrelin-induced growth hormone secretion in humans. (2000) (285)
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. (1998) (284)
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. (2008) (283)
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. (2004) (257)
New approach to the diagnosis of growth hormone deficiency in adults. (1996) (252)
Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. (2000) (240)
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. (2003) (233)
Consensus guidelines on screening for hypopituitarism following traumatic brain injury (2005) (231)
Consensus statement: medical management of acromegaly. (2005) (227)
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. (2012) (219)
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. (2004) (216)
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. (2004) (213)
A systematic literature review of reviews on techniques for physical activity measurement in adults: a DEDIPAC study (2018) (212)
Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. (1999) (212)
Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor (2005) (207)
Obestatin Promotes Survival of Pancreatic β-Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of β-Cell Mass and Function (2008) (190)
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. (2003) (185)
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement (2017) (179)
Predictors of morbidity and mortality in acromegaly: an Italian survey. (2012) (175)
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. (2013) (175)
Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland (2001) (169)
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. (2002) (166)
Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. (1986) (165)
The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. (2003) (164)
Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. (1990) (163)
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. (1994) (162)
Ghrelin drives GH secretion during fasting in man. (2002) (151)
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. (2020) (151)
Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. (1998) (141)
Ghrelin-producing endocrine tumors of the stomach and intestine. (2001) (138)
Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland (2001) (134)
Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans (2003) (133)
Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. (2003) (131)
The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state (2004) (126)
Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. (2003) (123)
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. (2001) (121)
Dual effects of IGFBP‐3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways (2004) (119)
Consuming More of Daily Caloric Intake at Dinner Predisposes to Obesity. A 6-Year Population-Based Prospective Cohort Study (2014) (117)
Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. (1999) (117)
Hypopituitarism (2007) (116)
The IGF system (2011) (115)
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term (2018) (114)
Circulating ghrelin levels as function of gender, pubertal status and adiposity in childhood (2002) (114)
Acetylcholine regulates ghrelin secretion in humans. (2004) (114)
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. (2002) (113)
Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. (2002) (112)
Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. (2007) (112)
Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. (2008) (111)
Heterogeneity of Ghrelin/Growth Hormone Secretagogue Receptors (2007) (110)
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. (2008) (110)
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. (2000) (110)
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables (2003) (109)
Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. (2003) (108)
Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. (2003) (108)
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology (2014) (106)
Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects. (1986) (106)
Sleep abnormalities in type 2 diabetes may be associated with glycemic control (2008) (105)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. (2009) (105)
Is the timing of caloric intake associated with variation in diet-induced thermogenesis and in the metabolic pattern? A randomized cross-over study (2015) (104)
Insulin‐like growth factor binding protein‐3 induces angiogenesis through IGF‐I‐ and SphK1‐dependent mechanisms (2007) (102)
The GH/IGF-I axis in obesity: influence of neuroendocrine and metabolic factors (2000) (101)
Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling. (1998) (100)
Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement (2015) (100)
Comparisons among old and new provocative tests of GH secretion in 178 normal adults. (2000) (99)
A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. (2008) (99)
The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. (1999) (98)
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. (2010) (97)
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients (1999) (96)
Endocrine and Non-Endocrine Actions of Ghrelin (2003) (94)
Growth Hormone-Releasing Peptides and Their Analogs (1998) (94)
Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. (2005) (94)
Gender and gonadal influences on ghrelin mRNA levels in rat stomach. (2001) (93)
Current management practices for acromegaly: an international survey (2011) (93)
Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. (2000) (93)
Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. (1991) (93)
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients (2012) (93)
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults (2008) (92)
Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. (1986) (92)
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults (2001) (92)
The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways (2012) (92)
ARGININE POTENTIATES THE GHRH‐ BUT NOT THE PYRIDOSTIGMINE‐INDUCED GH SECRETION IN NORMAL SHORT CHILDREN. FURTHER EVIDENCE FOR A SOMATOSTATIN SUPPRESSING EFFECT OF ARGININE (1990) (92)
Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. (1996) (91)
Obestatin regulates adipocyte function and protects against diet‐induced insulin resistance and inflammation (2012) (90)
Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH (1997) (89)
Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials (2018) (89)
The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. (1997) (88)
Growth hormone-releasing peptides. (1997) (88)
Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. (1997) (87)
Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission (2011) (85)
The GH‐releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans (2002) (85)
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor (2006) (84)
Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. (1996) (84)
Ghrelin secretion is inhibited by glucose load and insulin‐induced hypoglycaemia but unaffected by glucagon and arginine in humans (2004) (83)
Neuroregulation of the Hypothalamus-Pituitary-Adrenal (HPA) Axis in Humans: Effects of GABA-, Mineralocorticoid-, and GH-Secretagogue-Receptor Modulation (2006) (83)
Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. (2000) (83)
Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans (1999) (83)
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. (1994) (82)
Unacylated Ghrelin Rescues Endothelial Progenitor Cell Function in Individuals With Type 2 Diabetes (2010) (81)
Unacylated Ghrelin Promotes Skeletal Muscle Regeneration Following Hindlimb Ischemia via SOD‐2–Mediated miR‐221/222 Expression (2013) (80)
Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. (2002) (79)
The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. (2002) (79)
Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. (2010) (79)
Biologic activities of growth hormone secretagogues in humans (2001) (79)
Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. (2010) (78)
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. (2009) (77)
Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis (2019) (77)
Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease (2016) (77)
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. (1992) (76)
Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist. (1984) (76)
Neuroendocrine Alterations in Obese Patients with Sleep Apnea Syndrome (2010) (73)
Activity of GH/IGF‐I axis in patients with dilated cardiomyopathy (1999) (73)
Human aging and the GH-IGF-I axis. (1996) (72)
Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. (2012) (72)
Unacylated Ghrelin Induces Oxidative Stress Resistance in a Glucose Intolerance and Peripheral Artery Disease Mouse Model by Restoring Endothelial Cell miR-126 Expression (2014) (72)
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. (2007) (72)
Modulation of growth hormone-releasing activity of hexarelin in man. (1995) (72)
C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. (2012) (71)
Effects of glucose, free fatty acids or arginine load on the GH‐releasing activity of ghrelin in humans (2002) (70)
Diagnostic reliability of a single IGF‐I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency (2003) (70)
Diet-Gut Microbiota Interactions and Gestational Diabetes Mellitus (GDM) (2019) (69)
Hypopituitarism following traumatic brain injury. (2005) (69)
Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. (2007) (68)
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. (2007) (67)
Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. (2002) (67)
Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. (2008) (66)
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. (2005) (65)
Diagnosis of adult GH deficiency (2008) (65)
Diagnosis of adult GH deficiency. (2008) (65)
Unacylated as well as acylated ghrelin promotes cell survival and inhibit apoptosis in HIT-T15 pancreatic β -cells (2006) (64)
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone (2011) (63)
Hypothalamus–pituitary–adrenal axis evaluation in patients with hypothalamo–pituitary disorders: comparison of different provocative tests (2008) (63)
Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. (2002) (63)
Low dose (1 μg) ACTH test in the evaluation of adrenal dysfunction in pre‐clinical Addison's disease (2000) (63)
Growth hormone-releasing peptides and the cardiovascular system. (2000) (63)
Quantitative Value of Aldosterone‐Renin Ratio for Detection of Aldosterone‐Producing Adenoma: The Aldosterone‐Renin Ratio for Primary Aldosteronism (AQUARR) Study (2017) (61)
Role of mineralocorticoid receptors on the hypothalamus–pituitary–adrenal axis in humans (2013) (59)
Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. (2005) (59)
Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults (1998) (58)
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. (1995) (58)
Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism. (2001) (58)
Oral glucose load inhibits circulating ghrelin levels to the same extent in normal and obese children (2006) (58)
Marked GH secretion after ghrelin alone or combined with GH‐releasing hormone (GHRH) in obese patients (2004) (57)
Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients (2008) (57)
Cardiac effects of hexarelin in hypopituitary adults. (1999) (57)
Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. (2001) (56)
Glucose metabolism in patients with subclinical Cushing’s syndrome (2012) (55)
Ghrelin: endocrine, metabolic and cardiovascular actions. (2005) (55)
Involvement of the somatostatin and cholinergic systems in the mechanism of growth hormone autofeedback regulation in the rat. (1988) (55)
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial (2014) (55)
Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. (2018) (55)
Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency (1997) (54)
Circulating ghrelin levels in the newborn are positively associated with gestational age (2004) (54)
Hypopituitarism following traumatic brain injury (TBI): A guideline decalogue (2004) (54)
Obese patients with obstructive sleep apnoea syndrome show a peculiar alteration of the corticotroph but not of the thyrotroph and lactotroph function (2004) (53)
First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group (2006) (53)
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. (2004) (53)
Relationships between dehydroepiandrosterone‐sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women (1999) (52)
Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing’s Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses (2002) (52)
Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature. (1987) (52)
Endocrine and Non-Endocrine Activities of Growth Hormone Secretagogues in Humans (1999) (52)
Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. (1990) (52)
Hypopituitarism following brain injury: when does it occur and how best to test? (2012) (51)
Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. (2008) (50)
Metabolic and cardiovascular outcomes in a group of adult patients with Turner's syndrome under hormonal replacement therapy. (2011) (50)
Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. (1996) (50)
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). (2004) (50)
Des-acyl ghrelin fragments and analogues promote survival of pancreatic β-cells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. (2012) (49)
RFamide Peptides 43RFa and 26RFa Both Promote Survival of Pancreatic β-Cells and Human Pancreatic Islets but Exert Opposite Effects on Insulin Secretion (2014) (49)
Effects of Dexamethasone and Alprazolam, a Benzodiazepine, on the Stimulatory Effect of Hexarelin, a Synthetic GHRP, on ACTH, Cortisol and GH Secretion in Humans (1998) (49)
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. (1995) (48)
Ghrelin and the endocrine pancreas (2003) (48)
Cost-of-illness study in acromegalic patients in Italy (2004) (48)
Benzodiazepines and anterior pituitary function (2002) (48)
Brain–gut communication: cortistatin, somatostatin and ghrelin (2007) (48)
Changes in awakening Cortisol response and midnight salivary Cortisol are sensitive markers of strenuous training-induced fatigue (2008) (47)
The diagnosis of growth hormone deficiency in adults. (1997) (47)
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. (2009) (47)
Ghrelin and cortistatin in lung cancer: Expression of peptides and related receptors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line (2006) (47)
Ghrelin, Hypothalamus-Pituitary-Adrenal (HPA) Axis and Cushing's Syndrome (2005) (46)
Impact of Snacking Pattern on Overweight and Obesity Risk in a Cohort of 11- to 13-Year-Old Adolescents (2014) (46)
Elderly subjects show severe impairment of dehydroepiandrosterone sulphate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH1−24 (2001) (46)
Age-related Variations in the Neuroendocrine Control, More Than Impaired Receptor Sensitivity, Cause The Reduction in the GH-releasing Activity of GHRPs in Human Aging (1998) (46)
Normal age-dependent values of serum insulin growth factor-I: Results from a healthy Italian population (2007) (46)
Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly (2017) (46)
Corticotroph axis sensitivity after exercise: Comparison between elite athletes and sedentary subjects (2007) (46)
Pegvisomant in acromegaly: an update (2017) (46)
EP1572: A novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man (2002) (45)
Interaction of free fatty acids and arginine on growth hormone secretion in man. (1994) (45)
Tall stature without growth hormone: four male patients with aromatase deficiency. (2010) (45)
The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. (1997) (45)
Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. (1997) (45)
GHRH plus arginine in the diagnosis of acquired GH deficiency of childhood-onset. (2002) (45)
The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans (2008) (44)
Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours (2005) (44)
Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. (1999) (44)
Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. (2006) (44)
Variations of Pituitary Function Over Time after Brain Injuries: The Lesson from a Prospective Study (2006) (44)
Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. (1989) (44)
Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase γ and phosphodiesterase 3B. (2011) (43)
Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans. (2000) (43)
Critical assessment of the current guidelines for the management and treatment of morbidly obese patients (2007) (43)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study (2017) (43)
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. (1995) (42)
Orally active growth hormone secretagogues: state of the art and clinical perspectives. (1998) (42)
Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone (1989) (42)
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. (2009) (42)
Paediatric Pituitary Adenomas: A Decade of Change (2014) (42)
GPR103b functions in the peripheral regulation of adipogenesis. (2010) (42)
Diagnosis of GH deficiency in adults. (1998) (42)
Ghrelin: from somatotrope secretion to new perspectives in the regulation of peripheral metabolic functions. (2006) (42)
The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. (2002) (41)
Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. (1999) (41)
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients (1996) (41)
Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. (1991) (41)
Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH. (2001) (41)
Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: An update (2010) (41)
Insulin-Like Growth Factor I (2000) (40)
BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease (2012) (40)
ACROSTUDY: the Italian experience (2015) (40)
Endocrine Function Is Altered in Chronic Migraine Patients with Medication‐Overuse (2006) (39)
Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. (1997) (39)
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) (2019) (39)
Free fatty acids exert an inhibitory effect on adrenocorticotropin and cortisol secretion in humans. (2004) (39)
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. (2006) (38)
Ghrelin: endocrine and non-endocrine actions. (2002) (38)
The diagnosis of growth hormone deficiency (GHD) in adults. (1995) (37)
Pegvisomant in acromegaly: Why, when, how (2007) (37)
Endocrine actions of cortistatin: In vivo studies (2008) (37)
Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children. (1989) (37)
The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. (2002) (37)
Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. (2012) (37)
10 Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects (1998) (36)
Neurotransmitter Control of Growth Hormone Secretion in Humans (1993) (36)
Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects (1997) (36)
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. (1996) (36)
Growth hormone treatment in human ageing: benefits and risks (2008) (36)
Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. (1998) (36)
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration (1994) (35)
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms (2014) (35)
Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure (2017) (35)
Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects (1994) (35)
Neuroendocrine and metabolic determinants of the adaptation of GH/IGF-I axis to obesity. (2002) (35)
Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa. (2000) (35)
Obestatin: is it really doing something? (2014) (35)
Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement. (2009) (35)
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. (1999) (35)
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin‐induced hypoglycaemia in humans (2003) (35)
Endocrine responses to ghrelin in adult patients with isolated childhood‐onset growth hormone deficiency (2002) (35)
Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency (2001) (34)
Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease. (2011) (34)
Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion in somatotropes. (2006) (34)
Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3β Phosphorylation (2005) (34)
Clinical challenges with calcitonin-negative medullary thyroid carcinoma (2016) (33)
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. (1994) (33)
Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa (1994) (33)
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. (2013) (33)
Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test (1999) (33)
Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions (1998) (33)
Retesting the childhood-onset GH-deficient patient. (2008) (33)
Adipocyte-derived extracellular vesicles regulate survival and function of pancreatic β cells (2021) (33)
Circulating ghrelin levels in newborns are not associated to gender, body weight and hormonal parameters but depend on the type of delivery (2003) (33)
Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. (2020) (33)
Endocrine and metabolic actions of ghrelin. (2010) (33)
Traumatic Brain Injury and Hypopituitarism (2005) (33)
Hypothalamic Growth Hormone-Insulin-like Growth Factor-I Axis across the Human Life Span (2000) (33)
Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome. (1993) (32)
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly (2003) (32)
Growth hormone-inhibiting activity of cortistatin in the rat (2001) (32)
Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans. (2004) (32)
Both fasting‐induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity (2003) (32)
In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. (1995) (32)
Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women. (1997) (32)
Ghrelin and anterior pituitary function. (2010) (32)
A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone (1990) (32)
LONG‐TERM FOLLOW‐UP OF‘CURED’PROLACTINOMA PATIENTS AFTER SUCCESSFUL ADENOMECTOMY (1990) (31)
Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity (1994) (31)
Does use of metformin protect against cancer in Type 2 diabetes mellitus? (2012) (31)
Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man (1997) (31)
Age‐related growth hormone‐releasing activity of growth hormone secretagogues in humans (1997) (31)
The IGF‐I response to very low rhGH doses is preserved in human ageing (1998) (31)
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view (2020) (31)
The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. (1999) (30)
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. (2000) (30)
Evidence for Involvement of Endogenous Somatostatin in the Galanin-Induced Growth Hormone Secretion in Children (1990) (30)
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity (1999) (29)
Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. (1993) (29)
GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. (2013) (29)
The nutritional control of ghrelin secretion in humans (2006) (29)
The activity of GH/IGF-I axis in anorexia nervosa and in obesity: A comparison with normal subjects and patients with hypopituitarism or critical illness (1998) (29)
Obestatin: A new metabolic player in the pancreas and white adipose tissue (2013) (29)
Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. (2010) (29)
Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. (2002) (28)
Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. (1999) (28)
Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children. (1989) (28)
Interactions of galanin and arginine on growth hormone, prolactin, and insulin secretion in man. (1992) (28)
Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome (2015) (28)
Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans. (2000) (28)
GROWTH HORMONE RESPONSES TO PYRIDOSTIGMINE IN NORMAL ADULTS AND IN NORMAL AND SHORT CHILDREN (1987) (28)
Synergistic effect of growth hormone-releasing hormone (GHRH) and clonidine in stimulating GH release in young and old dogs (1990) (27)
Intracoronary ghrelin infusion decreases coronary blood flow in anesthetized pigs. (2007) (27)
Further Evidence of Cholinergic Impairment of the Neuroendocrine Control of the GH Secretion in Down’s Syndrome (1998) (27)
Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin (2002) (27)
Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death (2001) (27)
The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease. (2007) (27)
Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? (1993) (26)
Ghrelin and synthetic GH secretagogues. (2002) (26)
Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine. (2000) (26)
Presence of cortistatin in the human pancreas (2003) (26)
Impaired taste sensation in type 2 diabetic patients without chronic complications: a case–control study (2018) (26)
GH‐independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy (2002) (26)
GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses. (2012) (25)
Somatotropic function in short stature: Evaluation by integrated auxological and hormonal indices in 214 children (1993) (25)
Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa (2005) (25)
Insulin-Like Growth Factor I Levels and the Diagnosis of Adult Growth Hormone Deficiency (2005) (25)
Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism. (2013) (25)
Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of Developmental Pathways (2013) (25)
SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders (2009) (25)
Short‐term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects (2006) (25)
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma (2019) (25)
Standard light breakfast inhibits circulating ghrelin level to the same extent of oral glucose load in humans, despite different impact on glucose and insulin levels (2003) (25)
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans (2002) (25)
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. (2010) (25)
Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences. (2004) (25)
Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. (2003) (24)
Hypothalamic-Pituitary Autoimmunity and Traumatic Brain Injury (2015) (24)
Primary empty sella: Why and when to investigate hypothalamic-pituitary function. (2010) (24)
Central ghrelin production does not substantially contribute to systemic ghrelin concentrations: a study in two subjects with active acromegaly. (2002) (24)
Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia (1987) (24)
Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. (1992) (24)
Involvement of Nitric Oxide in the Regulation of Growth Hormone Secretion in Dogs (2001) (24)
Dehydroepiandrosterone, 17α‐hydroxyprogesterone and aldosterone responses to the low‐dose (1 µg) ACTH test in subjects with preclinical adrenal autoimmunity (2002) (24)
Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. The Italian Collaborative Group of Neuroendocrinology. (1993) (24)
Effects of Alpha‐ and Beta‐Adrenergic Agonists and Antagonists on Growth Hormone Secretion in Man (1990) (24)
ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease (2016) (23)
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. (2012) (23)
Unacylated ghrelin prevents mitochondrial dysfunction in a model of ischemia/reperfusion liver injury (2017) (23)
Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans (2003) (23)
Ghrelin: A Link between Eating Disorders, Obesity and Reproduction (2004) (23)
The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift. (2019) (23)
Effects of meal timing on changes in circulating epinephrine, norepinephrine, and acylated ghrelin concentrations: a pilot study (2017) (23)
Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine. (1993) (23)
In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. (2012) (23)
A Critical Review on the Role of Food and Nutrition in the Energy Balance (2020) (23)
Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid-β-induced toxicity (2016) (22)
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. (1995) (22)
Short Procedure of GHRH Plus Arginine Test in Clinical Practice (2001) (22)
Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man (1993) (22)
Possible contraindication of spironolactone during pregnancy (1979) (22)
Dehydroepiandrosterone sulfate levels in women. Relationships with age, body mass index and insulin levels (1999) (22)
Ghrelin does not mediate the somatotroph and corticotroph responses to the stimulatory effect of glucagon or insulin‐induced hypoglycaemia in humans (2004) (22)
GH secretion is impaired in patients with primary hyperparathyroidism. (2002) (22)
Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction (2009) (22)
Intravenous glucose administration in fasting rats has differential effects on acylated and unacylated ghrelin in the portal and systemic circulation: a comparison between portal and peripheral concentrations in anesthetized rats. (2007) (21)
Function of the GH/IGF-1 axis in healthy middle-aged male runners. (1996) (21)
Pluripotent stem cells isolated from human amniotic fluid and differentiation into pancreatic β-cells (2009) (21)
The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line. (2010) (21)
Growth hormone response to oral clonidine test in normal and short children (1993) (21)
Short‐term fasting in obesity fails to restore the blunted GH responsiveness to GH‐releasing hormone alone or combined with arginine (1995) (21)
Neural Control of Growth Hormone Secretion in Aged Humans (1993) (21)
The Role of Obestatin in Glucose and Lipid Metabolism (2013) (21)
In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. (1997) (21)
Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation. (2005) (20)
Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine. (1993) (20)
Growth Hormone Response to GHRH During Lifespan (1993) (20)
GH response to ghrelin in subjects with congenital GH deficiency: evidence that ghrelin action requires hypothalamic-pituitary connections. (2007) (20)
Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing’s disease (1999) (20)
Growth hormone secretagogues as corticotrophin-releasing factors. (1998) (20)
Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa (1999) (20)
Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man (1996) (20)
ACYLATED GHRELIN INHIBITS SPONTANEOUS LH PULSATILITY AND RESPONSIVENESS TO NALOXONE, BUT NOT THAT TO GnRH IN YOUNG MEN: EVIDENCE FOR A CENTRAL INHIBITORY ACTION OF GHRELIN ON THE GONADAL AXIS (2008) (20)
Male sexual disturbances in liver diseases: What do we know? (2010) (19)
Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children (1993) (19)
Early Copeptin Determination Allows Prompt Diagnosis of Post-Neurosurgical Central Diabetes Insipidus (2019) (19)
A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging (1992) (19)
The study of spontaneous GH secretion after 36‐h fasting distinguishes between GH‐deficient and normal adults (1999) (19)
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. (2008) (19)
Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease (2005) (19)
Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects (2014) (18)
Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa (1998) (18)
Ghrelin: much more than a natural growth hormone secretagogue. (2002) (18)
GH-Releasing Hormone Promotes Survival and Prevents TNF-α-Induced Apoptosis and Atrophy in C2C12 Myotubes. (2015) (18)
Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. (1999) (18)
Adrenal responsiveness to high, low and very low ACTH 1–24 doses in obesity (2000) (18)
The growth hormone secretagogue receptor. (1999) (18)
Neuroendocrine Control of Growth Hormone Secretion (1989) (18)
The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors (2016) (17)
Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. (1996) (17)
Management of GH treatment in adult GH deficiency. (2017) (17)
Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy (2001) (17)
Hypopituitarism following traumatic brain injury. (2005) (17)
Glucagon Is an ACTH Secretagogue as Effective as hCRH after Intramuscolar Administration while It Is Ineffective When Given Intravenously in Normal Subjects (2000) (17)
Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in female primates and male/female mice. (2014) (17)
Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction (2000) (17)
The effectiveness of arginine + GHRH test compared with GHRH + GHRP‐6 test in diagnosing growth hormone deficiency in adults (2003) (17)
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in humans (1999) (17)
Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. (1998) (17)
Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man (1997) (17)
Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH‐stimulated GH secretion in humans (1994) (17)
Somatopause reflects age-related changes in the neural control of GH/IGF-I axis. (2005) (16)
Ghrelin secretion in preterm neonates progressively increases and is refractory to the inhibitory effect of food intake. (2006) (16)
Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy (2019) (16)
Neonatal and adult human heart tissues from normal subjects and patients with ischemic, dilated or hypertrophic cardiomyopathy express insulin-like growth factor binding protein-3 (IGFBP-3) (2000) (16)
Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging. (1995) (16)
Neuroendocrine and metabolic activities of ghrelin gene products (2011) (16)
Defective regulation of prolactin secretion after successful removal of prolactinomas. (1983) (16)
Effects of alpha- and beta-adrenergic agonists and antagonists on growth hormone secretion in man. (1990) (16)
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. (1995) (16)
Hormonal diagnosis of GH hypersecretory states. (2003) (16)
Should every patient with traumatic brain injury be referred to an endocrinologist? (2007) (16)
Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY. (2016) (16)
Traumatic brain injury and hypopituitarism in children and adolescents: is the problem under-estimated? (2007) (15)
The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. (2005) (15)
Managing patients with hypopituitarism after traumatic brain injury (2007) (15)
DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacement (2000) (15)
Corticotrope hypersecretion coupled with cortisol hypo-responsiveness to stimuli is present in patients with autoimmune endocrine diseases: evidence for subclinical primary hypoadrenalism? (2006) (15)
Hyperthyroidism in patients with ischaemic heart disease after iodine load induced by coronary angiography: Long‐term follow‐up and influence of baseline thyroid functional status (2018) (15)
Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome. (2009) (15)
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. (1996) (15)
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. (1998) (15)
Galanin reinstates the growth hormone response to repeated growth hormone‐releasing hormone administration in man (1992) (14)
Growth hormone secretagogues : basic findings and clinical implications (1999) (14)
Other than growth hormone neuroendocrine actions of ghrelin. (2013) (14)
Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans. (1994) (14)
Urinary cortisol and psychopathology in obese binge eating subjects (2014) (14)
Failure of pyridostigmine to increase both basal and GHRH-induced GH secretion in the night. (1990) (14)
The Regulation of Growth Hormone Secretion (1999) (14)
Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment (2021) (14)
Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion. (2013) (14)
Hormones and athletic performance (2011) (14)
Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: Different behavior patterns? (2002) (14)
Hypopituitarism following traumatic brain injury (TBI): call for attention. (2005) (14)
Pituitary Autoimmunity. (2017) (14)
Treatment of acromegaly with SS analogues: Should GH and IGF-I target levels be lowered to assert a tight control of the disease? (2004) (14)
Higher protein intake is associated with improved muscle strength in elite senior athletes. (2017) (14)
Products of the ghrelin gene, the pancreatic β-cell and the adipocyte. (2013) (13)
Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? (2016) (13)
Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency. (2001) (13)
Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine (2001) (13)
Aging and Growth Hormone Releasing Peptides (1996) (13)
Mediterranean Diet and SARS-COV-2 Infection: Is There Any Association? A Proof-of-Concept Study (2021) (13)
Cushing’s syndrome is associated with sleep alterations detected by wrist actigraphy (2015) (13)
Treatment of Acromegalic Osteopathy in Real-Life Clinical Practice: The BAAC (Bone Active drugs in ACromegaly) Study. (2020) (13)
Is GH therapy useful to preserve bone mass in transition-phase patients with GH deficiency? (2005) (13)
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood (2007) (13)
Predictors of attrition from a weight loss program. A study of adult patients with obesity in a community setting (2020) (13)
Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women (1998) (13)
Insulin-like growth factor binding protein-3 mediates serum starvation- and doxorubicin-induced apoptosis in H9c2 cardiac cells (2003) (13)
A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care. (2010) (13)
Enhanced adrenocorticotrophic hormone and cortisol responses to corticotrophin-releasing hormone in central idiopathic diabetes insipidus. (1994) (13)
Pluripotent stem cells isolated from human amniotic fluid and differentiation into pancreatic beta-cells. (2009) (13)
Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans (2003) (13)
Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN) (2020) (12)
Neuroendocrine effects of citalopram infusion in anorexia nervosa (2006) (12)
Growth Hormone Stimulation Tests in Pediatrics (2004) (12)
Targeting the ghrelin receptor (2003) (12)
Corticotropin-Releasing Effect of Hexarelin, a Peptidyl GH Secretagogue, in Normal Subjects Pretreated with Metyrapone or RU-486, a Glucocorticoid Receptor Antagonist, and in Patients with Addison’s Disease (1999) (12)
Myocardial insulin-like growth factor-1 and insulin-like growth factor binding protein-3 gene expression in failing hearts harvested from patients undergoing cardiac transplantation. (2009) (12)
Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans (2001) (12)
Galanin positively modulates prolactin secretion in normal women (1996) (12)
The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic–pituitary–adrenal (HPA) axis in humans (2013) (12)
Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood. (1996) (12)
GHRH and GH secretagogues: clinical perspectives and safety. (2004) (12)
Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children (1993) (12)
Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa (2000) (12)
Sequential administration of arginine and arginine plus GHRH to test somatotroph function in short children (2000) (12)
Pre-operative micronutrient deficiencies in patients with severe obesity candidates for bariatric surgery (2020) (12)
The exon 3-deleted growth hormone receptor: Molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions (2011) (12)
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. (1987) (12)
Growth hormone-releasing factor does not stimulate phosphoinositides breakdown in primary cultures of rat and human pituitary cells. (1986) (12)
Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. (2000) (12)
The importance of investigation of pituitary function in children and adolescents following traumatic brain injury (2006) (12)
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1–24) independently of the duration of the disease (2003) (12)
Rare diseases in clinical endocrinology: a taxonomic classification system (2015) (12)
Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity. (2001) (12)
The adrenal sensitivity to ACTH stimulation is preserved in anorexia nervosa (2004) (12)
Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia (1987) (12)
Corticotrophin-releasing hormone does not inhibit growth hormone-releasing hormone-induced release of growth hormone in control subjects but is effective in patients with eating disorders. (1994) (12)
Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. (2019) (11)
Growth hormone deficiency in the transition adolescent: should treatment be continued in adult life? (2001) (11)
Cholinergic enhancement of pyridostigmine potentiates spontaneous diurnal but not nocturnal growth hormone secretion in short children. (1989) (11)
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas (2015) (11)
Circulating obestatin levels in normal and Type 2 diabetic subjects (2010) (11)
The Ghrelin System (2013) (11)
Strategies for Reducing Salt and Sugar Intakes in Individuals at Increased Cardiometabolic Risk (2021) (11)
Reference ranges of late-night salivary cortisol and cortisone measured by LC–MS/MS and accuracy for the diagnosis of Cushing’s syndrome (2020) (11)
Structural and molecular adaptations to dexamethasone and unacylated ghrelin administration in skeletal muscle of the mice. (2018) (11)
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. (1996) (11)
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group (2011) (11)
Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system. (2001) (11)
PROLACTIN AND TSH RESPONSES TO BOTH DOMPERIDONE AND TRH IN NORMAL AND HYPERPROLACTINAEMIC WOMEN AFTER DOPAMINE SYNTHESIS BLOCKADE (1985) (11)
Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects (1998) (11)
Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans. (2000) (11)
Hormone Use and Abuse by Athletes (2011) (10)
IGF-I levels in prepubertal and pubertal children with Down syndrome. (1998) (10)
Effects of Alprazolam, a Benzodiazepine, on the ACTH-, GH- and PRL-Releasing Activity of Hexarelin, a Synthetic Peptidyl GH Secretagogue (GHS), in Patients with Simple Obesity and in Patients with Cushing's Disease (1999) (10)
The GH-Releasing Effect of Hexarelin, a Synthetic Hexapeptide, in Newborns is Lower than in Young Adults (1997) (10)
Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. (2002) (10)
Association of craniopharyngioma and pituitary adenoma (2013) (10)
Aspects of neurotransmitter control of GH secretion: basic and clinical studies (1989) (10)
There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients (2004) (10)
[Growth hormone and lipids]. (1997) (10)
Endocrine and Nonendocrine Actions of Ghrelin and GHS: State of the Art in Clinic Research (2003) (9)
Fracture risk assessment in an Italian group of transgender women after gender-confirming surgery (2020) (9)
Adrenal sensitivity to adrenocorticotropin 1-24 is reduced in patients with autoimmune polyglandular syndrome. (2004) (9)
Natural and Synthetic Growth Hormone Secretagogues (2003) (9)
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. (1999) (9)
Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. (2021) (9)
Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland (2001) (9)
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes Short Title: Effects of AG and UAG in morbid obesity (2009) (9)
Low Hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH‐induced GH response in man (1997) (9)
Ghrelin: more than a new frontier in neuroendocrinology. (2004) (9)
Effects of Subcutaneous Sumatriptan on Plasma Growth Hormone Concentrations in Migraine Patients (2000) (9)
Unacylated ghrelin ( UnAG ) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression (2014) (9)
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study (2020) (9)
Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children. (1990) (9)
d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans (2007) (9)
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. (2009) (8)
Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity (1997) (8)
Hormone treatment in gender dysphoria (2008) (8)
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis (2022) (8)
The Italian Endo-COVID-19. Our response to the emergency (2020) (8)
Effects of free fatty acids on ACTH and cortisol secretion in anorexia nervosa. (2006) (8)
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study (2008) (8)
Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to snort-term fasting in acromegaly (2008) (8)
The diagnostic accuracy of adjusted unconventional indices for adrenal vein sampling in the diagnosis of primary aldosteronism subtypes (2020) (8)
Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells (2020) (8)
Hyperprolactinemia: neuroendocrine and diagnostic aspects (1989) (8)
Ghrelin Actions on Somatotropic and Gonadotropic Function in Humans. (2016) (8)
Control and function of the GH-IGF-I axis in obesity. (2001) (8)
Effect of testosterone replacement therapy on the somatotrope responsiveness to GHRH alone or combined with pyridostigmine and on sympathoadrenal activity in patients with hypogonadism (1995) (8)
Effects of Phenylalanine, Histidine, and Leucine on Basal and GHRH-stimulated GH Secretion and on PRL, Insulin, and Glucose Levels in Short Children. Comparison with the Effects of Arginine (1996) (8)
Pyroglutamylated RF-amide peptide (QRFP) gene is regulated by metabolic endotoxemia. (2014) (8)
Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patients (2007) (7)
PEAK GH RESPONSE TO VARIOUS PROVOCATIVE STIMULI IN CHILDREN WITH NORMAL AND FAMILIAL SHORT STATURE (1993) (7)
Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up (2016) (7)
IGF-1 levels in different conditions of low somatotrope secretion in adulthood: obesity in comparison with GH deficiency. (1999) (7)
The Cut-off Limits of Growth Hormone Response to the Insulin Tolerance Test Related to Body Mass Index for the Diagnosis of Adult Growth Hormone Deficiency (2020) (7)
Testing pituitary function in aging individuals. (2005) (7)
Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans (2008) (7)
[Endocrine abnormalities in anorexia nervosa]. (2003) (7)
GH Secretagogues in Aging (2000) (7)
H9c2 cardiac muscle cells express all somatostatin receptor subtypes (2004) (7)
Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands (2001) (7)
Arginine-induced hypophosphatemia and hyperkaliemia in man. (1979) (7)
Activity of GH/IGF-1 axis in burn patients: Comparison with normal subjects and patients with GH deficiency (2002) (7)
Ghrelin: a new hormone with endocrine and non-endocrine activities. (2004) (7)
Natural and Synthetic Growth Hormone Secretagogues: Endocrine and Nonendocrine Activities Suggesting Their Potential Usefulness as Anti-Aging Drug Interventions (2001) (7)
Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children. (1990) (7)
Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism (2003) (7)
Unacylated ghrelin (UAG) enhances the early insulin response to meal, improves glucose metabolism and decreases free fatty acids levels in healthy volunteers (2007) (6)
Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. (2015) (6)
The impact of real practice inappropriateness and devices’ inefficiency to variability in growth hormone consumption (2014) (6)
IGFs and IGFBPs in adult growth hormone deficiency. (2005) (6)
A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care (2010) (6)
Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy (2018) (6)
Morning Serum Cortisol Level Predicts Central Adrenal Insufficiency Diagnosed by Insulin Tolerance Test (2021) (6)
Somatostatin, cortistatin and their receptors in health and disease. Foreword. (2008) (6)
Second-Day Morning Cortisol Levels after Transsphenoidal Surgery Are Accurate Predictors of Secondary Adrenal Insufficiency with Diagnostic Cut-Offs Similar to Those in Non-Stressed Conditions (2020) (6)
The incidence of the refeeding syndrome. A systematic review and meta-analyses of literature. (2021) (6)
Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia (2022) (6)
Impaired GH secretion to provocative stimuli in two families with hypocalciuric hypercalcaemia (2003) (6)
The Effects of Time-Restricted Eating on Metabolism and Gut Microbiota: A Real-Life Study (2022) (6)
Natural and synthetic growth hormone secretagogues: do they have therapeutic potential? (2003) (6)
The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: What to keep and what to amend? (2007) (5)
Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy (2000) (5)
What predicts the unsuccess of bariatric surgery? An observational retrospective study (2020) (5)
Beta‐adrenergic agonism does not impair the GH response to acylated ghrelin in humans (2009) (5)
GH response to GHRH, insulin, clonidine and arginine after GHRH pretreatment in children. (1992) (5)
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life (2022) (5)
Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children. (1991) (5)
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. (1999) (5)
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study (2020) (5)
ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. (2020) (5)
The effects of Clonidine on blood pressure, catecholamine and growth hormone release in hypogonadal men is preserved and not influenced by testosterone replacement therapy (1996) (5)
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. (1992) (5)
The GH-releasing effect of acylated ghrelin in normal subjects is refractory to GH acute auto-feedback but is inhibited after short-term GH administration inducing IGF1 increase. (2013) (5)
Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children (1989) (5)
Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity (2002) (5)
Known and Unknown Growth Hormone Secretagogue Receptors and their Ligands (2004) (5)
Age-related variations of the GH response to GH secretagogues in humans. (2002) (5)
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients (2000) (5)
Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia. (1983) (5)
Ghrelin and other gastrointestinal peptides involved in the control of food intake. (2007) (5)
The negative GH auto-feedback in childhood: Effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children (2000) (5)
Chapter 12 – Hormonal Activities of Growth Hormone Secretagogues (GHS) across Human Lifespan (1999) (5)
Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience (2021) (5)
Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia (1985) (4)
Mycobiota composition and changes across pregnancy in patients with gestational diabetes mellitus (GDM) (2022) (4)
Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea (2011) (4)
Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans (1995) (4)
The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. (1999) (4)
Primary hyperaldosteronism is associated with derangement in the regulation of the hypothalamus-pituitary-adrenal axis in humans (2007) (4)
IGF-I levels in different conditions of low somatotrope secretion in adulthood: obesity in comparison with GH deficiency. (1998) (4)
Diabetes Secondary to Endocrine and Pancreatic Disorders (2014) (4)
Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa (2003) (4)
Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe (2022) (4)
Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension (1998) (4)
The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison’s disease (2016) (4)
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight (2022) (4)
Impact of Snacking Pattern on Overweight and Obesity Risk in A Cohort of 11-13-y Adolescents (4)
Primary hyperparathyroidism is associated with marked impairment of GH response to acylated ghrelin (2008) (4)
Long-term treatment of acromegaly with pegvisomant (Somavert): cross-sectional observations from ACROSTUDY, a post-marketing, international, safety, surveillance study (2011) (4)
Pituitary apoplexy in acromegaly after pituitary computed tomography: spontaneous or induced? (1986) (4)
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. (1997) (4)
GH Secretion in Prader-Labhard-Willi Syndrome: Somatotrope Responsiveness to GHRH is Enhanced by Arginine but not by Pryidostigmine (1996) (4)
Correction: Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of Developmental Pathways (2013) (4)
Further evidence against a stimulatory role of the cholinergic system on the hypothalamic pituitary adrenal axis in man (1990) (4)
Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia. (1986) (4)
Development and validation of a scoring system for pre-surgical and early post-surgical prediction of bariatric surgery unsuccess at 2 years (2021) (4)
Activation of pituitary axis according to underlying critical illness and its effect on outcome. (2019) (4)
Suppression and recovery of LH secretion by a potent and selective GnRH‐receptor antagonist peptide in healthy early follicular‐phase women are mediated via selective control of LH secretory burst mass (2003) (4)
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment (2020) (4)
Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus–pituitary disease (2015) (4)
Evaluation of GH deficiency by GHRH+arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. (2002) (4)
Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature. (2014) (3)
Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with PCO syndrome (2009) (3)
Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans. (2008) (3)
Human Ageing and the Growth Hormone/Insulin-Like Growth Factor-I(GH/IGF-I) Axis - The Impact of Growth Factors on Dementia (2012) (3)
Do glucocorticoids induce addiction in humans? (2017) (3)
Impact of Allogeneic Stem Cell Transplantation on Testicular and Sexual Function. (2021) (3)
Non-Celiac Gluten/Wheat Sensitivity: Clinical Characteristics and Microbiota and Mycobiota Composition by Response to the Gluten Challenge Test (2021) (3)
Methionine potentiates both basal and GHRH‐induced GH secretion in children (1997) (3)
Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity (1996) (3)
The Accuracy of Simple and Adjusted Aldosterone Indices for Assessing Selectivity and Lateralization of Adrenal Vein Sampling in the Diagnosis of Primary Aldosteronism Subtypes (2022) (3)
Foreword. Glucocorticoid-induced osteoporosis. (2008) (3)
Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Hypersecretory States (2012) (3)
Similarity of the nocturnal profile of serum melatonin at early puberty and early adulthood. (1992) (3)
Pyridostigmine plus GHRH is the Most Powerful Single Test of the Secretory Integrity of Somatotrophs (1988) (3)
Growth hormone releasing activity of hexarelin in Down syndrome (1996) (3)
Atrial Fibrillation and Aortic Ectasia as Complications of Primary Aldosteronism: Focus on Pathophysiological Aspects (2022) (3)
Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children. (1993) (3)
Increased frequency of impaired fasting glucose and isolated systolic hypertension in Paget’s disease of bone (2018) (3)
Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone (2022) (3)
Endocrinology and art. Acromegaly and goiter in the Pre-Columbian, Mesoamerican population. (2007) (3)
Adipose Tissue Dysfunction in Obesity: Role of Mineralocorticoid Receptor (2022) (3)
Endocrinology and art (2007) (3)
Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing’s syndrome (2013) (2)
Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling (2021) (2)
Affective temperaments and obesity: Is there an association with binge eating episodes and multiple weight cycling? (2021) (2)
Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia (1984) (2)
A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly (2007) (2)
Effect of Bariatric Surgery on Survival and Hospitalizations in Patients with Severe Obesity. A Retrospective Cohort Study (2021) (2)
PubMed search strategies for the identification of etiologic associations between hypothalamic-pituitary disorders and other medical conditions (2013) (2)
Development and Internal Validation of a Predictive Model for Adult GH Deficiency Prior to Stimulation Tests (2021) (2)
Contents, Vol. 4, 1993 (1993) (2)
Effect of 1-year oral cholecalciferol on a metabolic profile and blood pressure in poor-controlled type 2 diabetes mellitus: an open-label randomized controlled pilot study (2020) (2)
Impact of refeeding syndrome on short- and medium-term all-cause mortality: a systematic review and meta-analysis. (2021) (2)
Hypopituitarism in Adults and Children following Traumatic Brain Injury (2007) (2)
Effect of digoxin on the somatotroph responsiveness to growth hormone‐releasing hormone (GHRH) alone or combined with arginine in normal young volunteers (2001) (2)
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients (2012) (2)
Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine. (1990) (2)
Cortistatin: Not Simply a Natural Somatostatin Analogue (2003) (2)
Effects of hexarelin, A synthetic GH-releasing hexapeptide, In humans (1995) (2)
62. Spironolactone as an antiandrogen in the therapy of female hirsutism (1979) (2)
Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients (1997) (2)
Function of GH/IGF-I axis in aging: Multicenter study in 152 healthy elderly subjects with different degrees of physical activity: Italian Association for Research on Brain Aging (AIRIC) Multicenter Study Group (1997) (2)
Endocrine Responses to GH Secretagogues in Relation to Sex and Age in Humans (1999) (2)
Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study (2021) (2)
Correction to: Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis (2020) (2)
The IGF-I response to very low rhGH doses is preserved in human aging. (1999) (2)
H9c2 cardiac muscle cells express insulin-like growth factor binding protein-3 (IGFBP-3). (2002) (2)
Clinical Manifestations of Primary Hyperparathyroidism (2016) (2)
Neuroendocrine effects of Citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans (2010) (2)
Prolactin and TSH response to alpha-methyl-l-tyrosine in normal subjects and in women with pathological hyperprolactinemia. (1985) (2)
Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. (2022) (2)
Court dwarfs: an overview of European paintings from fifteenth to eighteenth century (2012) (2)
Primary hyperparathyroidism and skeleton. Foreword. (2011) (2)
Impervious peptides as growth hormone secretagogues (1999) (2)
Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience (2021) (2)
Failure of cholinergic agonists and antagonists ot modify the GH response to GHRH in acromegaly (1990) (1)
Development of a Prediction Model of Disease Activity in Support of Clinical Practice - the Acrodat Experience. (2015) (1)
Effect of IGF-I administration on growth hormone secretion in obese subjects (2001) (1)
Absence of alterations in plasma levels of various hypophyseal hormones after administration of cytidine-diphosphate-coline. (1982) (1)
Hypopituitarism following Traumatic Brain Injury (2007) (1)
Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity (2020) (1)
Continuous glucose monitoring enhances the diagnostic value of mixed meal test in reactive hypoglycemia (2011) (1)
Inheritance of female unexplained hirsutism. (1981) (1)
Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic disorders in people living with HIV. (2022) (1)
Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study (2022) (1)
The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects. (2022) (1)
Trabecular Bone Score as an Index of Bone Fragility in Patients with Acromegaly: A Systematic Review and Meta-Analysis (2022) (1)
Mary with Child and Saints — Palma il Vecchio (2013) (1)
From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma (2022) (1)
A Simplified Ultrasonographic Score for the Prediction of Cytologically Suspicious Thyroid Nodules (2020) (1)
In Patients with Obesity, Are Affective Temperaments Associated with Attrition? An Evaluation during and before the SARS-CoV-2 Pandemic (2022) (1)
First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence (2021) (1)
Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma (2022) (1)
Neuroactive Drugs in Growth Disorders (1990) (1)
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study (2020) (1)
Hexarelin-stimulated growth hormone secretion in patients on maintenance haemodialysis (1998) (1)
Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Deficiency States (2012) (1)
Identification of risk conditions for the development of adrenal disorders: how optimized PubMed search strategies makes the difference (2014) (1)
Screening for Hypopituitarism Following Traumatic Brain Injury (TBI) (2006) (1)
Combining growth hormone releasing hormone-arginine and synacthen testing diminishes the cortisol response. (2007) (1)
Adrenal sensitivity to ACTH1-24 as function of age, body weight and pituitary function. (2002) (1)
PATIENTS WITH AUTOIMMUNE DISEASES SHOWED ENHANCED BASAL AND STIMULATED CORTICOTROPH SECRETION (2005) (1)
TSH response to domperidone. (1986) (1)
Prolactin secretion in patients with polycystic ovary syndrome. (1985) (1)
Retrospective analysis of the ultrasound features of resected thyroid nodules (2020) (1)
Young adults with Down's syndrome show increased corticotrope responsiveness to hCRH or hexarelin, a peptidyl GH secretagogue. (1999) (1)
Erratum to Hypopituitarism following traumatic brain injury (TBI): A guideline decalogue (2014) (1)
Ghrelin as a New Factor in the Central Network Controlling Appetite and Food Intake (2006) (1)
MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis (2022) (1)
Corrigendum to "Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism" [Growth Horm. IGF Res. 23 (4) (2013) 109-113] (2014) (1)
Acute assessment of subjective appetite and implicated hormones after a hypnosis-induced hallucinated meal: a randomized cross-over pilot trial (2020) (1)
Endocrinopathy-induced osteoporosis. Impact on health and economics of osteoporosis. (2010) (1)
Pituitary computed tomography and dynamic tests of prolactin and thyrotropin secretion in 103 hyperprolactinemic patients. (1987) (1)
A retrospective study on the association between urine metanephrines and cardiometabolic risk in patients with nonfunctioning adrenal incidentaloma (2022) (1)
Metabolic disorders and hypertension in mild primary hyperparathyroidism (2012) (1)
Intermittent Growth Hormone‐Releasing Hormone Administration Unravels Different Growth Hormone Secretory Patterns in Normal Adults and Children (1989) (1)
Effect of Six-Months Supplementation with Cholecalciferol on Glycemic and Blood Pressure Control in Elderly Type 2 Diabetic Patients with Vitamin D Deficiency: A Pilot Study (2018) (1)
Mesenchymal stem cells-derived microvesicles modulate cellular immune response to islet antigen GAD in type 1 diabetes. (2012) (1)
Ghrelin in the Regulation of GH Secretion and Other Pituitary Hormones (2011) (1)
Saluto dei Direttori Scientifici (2012) (1)
Väinö Myllyrinne: The World’s Tallest Acromegalic Soldier on a Postcard (2013) (1)
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. (1998) (1)
Uptodate on GH/IGF-1 axis actions (2013) (1)
Agromegaly and Goiter in the Pre-Columbian, Mesoamerican Population (2007) (1)
The prevalence of silent acromegaly in prolactinomas is very low (2020) (1)
Age-related variations in the growth hormone response to growth hormone secretagogues (1998) (1)
Usefulness of insulin-like growth factor I levels in the diagnosis of growth hormone deficiency in adults (1998) (1)
Nutritional parameters in patients with severe catabolism due to trauma or sepsis (1997) (1)
Positive Metabolic Impact of Treatment with Pegvisomant in an Acromegalic Patient (2007) (0)
GH and leptin secretion in humans Short-term fasting abolishes the sex-related difference in (2016) (0)
Traumatic brain injury (TBI) and lipid profile abnormalities: study 12 months after the brain injury (2007) (0)
EARLY ENDOCRINE DYSFUNCTION IN CRITICAL ILLNESS OF DIFFERENT AETIOLOGY (2014) (0)
FEMALE PATIENTS WITH DOWN SYNDROME (DS) SHOW A GREATER INSULIN RESISTANCE IN COMPARISON WITH NORMAL FEMALES (NF) (2003) (0)
Subjective and objective sleep evaluation in patients with hypo- and hyper-thyroidism (2009) (0)
Effects of the ghrelin gene-derived peptides on adipose browning and thermogenesis (2021) (0)
Endocrinopathy-induced osteoporosis. Fourth National Meeting, Ancona, Italy, September 25-26, 2008. (2009) (0)
Society for Endocrinology European Medal Lecture (2003) (0)
Steroidomic approach for the characterization of patients with non-alcoholic fatty liver disease (2022) (0)
The GH response to GHRH in normal adults is not affected by enalapril or furosemide while is blunted by digoxin. (1999) (0)
Obestatin exerts post-conditioning-like cardioprotective effects via nitrosative/oxidative signaling (2015) (0)
AENDO June 39/6 (1999) (0)
Idiopathic primary hyperaldosteronism frequently undergoes spontaneous remission: frequence and predictors (2012) (0)
SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience (2019) (0)
Biliary stone disease in acromegaly under somatostatinanalogues: A longterm safety study (2020) (0)
Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma (2023) (0)
Introduction (2009) (0)
Ghrelin: a neuroendocrine and/or a metabolic story? (2011) (0)
Giovanni Faglia (1930–2012) (2012) (0)
NEW MECHANISMS IN THE CONTROL OF GROWTH HORMONE SECRETION (2003) (0)
HYPERCORTISOLISM DUE TO CUSHING’S DISEASE IS ASSOCIATED TO DERANGED GHRELIN SECRETION AND ACTION (2005) (0)
Glucocorticoid receptor polymorphisms and metabolic-cardiovascular impairment in adult patients with Addison's disease under glucocorticoid replacement therapy (2010) (0)
Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe (2021) (0)
QRFP induces β-cell and human islet cell survival and insulin secretion and promotes glucose uptake in β-cells, adipocytes and muscle cells (2009) (0)
“Cured” Prolactinoma Patients After Transsphenoidal Adenomectomy: Prediction of Recurrence (1989) (0)
Muscle fiber conduction slowing is a sensitive marker of steroid myopathy in Cushing’s disease (2011) (0)
Clinical and Pathological Tools for Predicting Recurrence and/or Metastasis in Patients with Pheochromocytoma and Paraganglioma (2022) (0)
Activity of GH/IGF-I axis in catabolic patients with sepsis or trauma (1997) (0)
Ghrelin inhibits LH pulsatile secretion in humans. (2006) (0)
Prevalence, type and evolution of autoimmune diseases with respect to hormone control in patients with cortisol, GH and prolactin hypersecretion (2022) (0)
GHRELIN AND SYNTHETIC GHS (2003) (0)
Thyroid nodule ultrasound: which indication for FNA? a prospective study (2016) (0)
Dehydroepiandrosterone positively affects nitric oxide production in platelets of normal subjects. (2006) (0)
Early detection of antipituitary antibodies and pituitary dysfunction in patients with severe traumatic brain injury (2013) (0)
Growth Hormone-Releasing Hormone (GHRH) exerts protective effects on adult rat hippocampal progenitor cells (2007) (0)
Abstract #1403093: Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome (2023) (0)
SOMATOSTATIN, SOMATOSTATIN ANALOGUES AND CORTISTATIN REDUCE PDGF-INDUCED ENDOMETRIAL CELL PROLIFERATION AND MOTILITY (2009) (0)
Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension (2020) (0)
THE INHIBITORY EFFECT OF BETA 2ADRENORECEPTOR ACTIVATION BY SALBUTAMOL ON GH SECRETION IS AGE-DEPENDENT (1995) (0)
Ghrelin exerts an inhibitory modulation on LH pulsatility in humans. (2006) (0)
Effects of CST-8, a synthetic cortistatin analogue, in humans (2007) (0)
Metabolic and cardiovascular profile in adult patients with addison's disease under conventional glucocorticoid replacement therapy (2008) (0)
P.6.034 Endocrine responses to ghrelin in patients with eating disorders (2003) (0)
Cortisol and dexamethasone exert different negative feedback action in humans (2007) (0)
IGF1 levels as predictor factor of metabolic derangement in adult patients with severe GH deficiency (2010) (0)
Effect of acipimox, an antilipolytic substance, on GH secretion in obesity (1995) (0)
Subject Index Vol. 43, 1986 (1986) (0)
Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells (2020) (0)
Ghrelin: what do we know about its role in health and disease? (2006) (0)
Predictive performance of aldosterone-to-renin ratio in the diagnosis of primary aldosteronism in patients with resistant hypertension (2023) (0)
Hypothalamic-Pituitary Diseases (2018) (0)
Acute effects of acylated ghrelin on salbutamol-induced metabolic actions in humans (2015) (0)
Endometriotic cell proliferation and survival are inhibited by somatostatin analogues and GHRH antagonists (2008) (0)
Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery (2022) (0)
EFFECT OF hCRH, VASOPRESSIN, ALPRAZOLAM AND DEXAMETHASONE ON THE ACTH AND CORTISOL RESPONSES TO HEXARELIN, A SYNTHETIC GHRP, IN HUMANS (1997) (0)
Subject Index Vol. 67, Suppl. 1, 2007 (2007) (0)
Basal and stimulated GH secretion in Cushing's syndrome: effects of ghrelin and GHRH+arginine (2010) (0)
Sensitivity and specificity of different provocative tests for the diagnosis of secondary hypoadrenalism in patients with hypothalamo-pituitary disorders (2006) (0)
Growth hormone-releasing hormone prevents cardiomyocyte apoptosis and activated PI3K/AKT, ERK1/2 and CREB signaling pathways (2007) (0)
Foreword (2008) (0)
GH and cortisol secretion in patients with burn on day 7 after thermal injury (2000) (0)
Efficacy and safety of long-term high doses of cabergoline in prolactin secreting tumor (2022) (0)
Franco Camanni (1930–2019) (2019) (0)
Body Weight Regulation and Hypothalamic Neuropeptides (2006) (0)
Contents, Vol. 63, 1996 (1996) (0)
Criteria for disease control in acromegaly under SSA treatment: mean GH profile or GH random? (2015) (0)
P.8.050 Neuroendocrine response to intravenous citalopram infusion in anorexia nervosa (2005) (0)
Response to the letter: ‘Octanoylated and nonoctanoylated ghrelin levels in cord blood’ by S. Ferrero (2004) (0)
growth and adaptation Mechanical signal transduction in skeletal muscle (2015) (0)
unacylated ghrelin recovers neovascularization in diabetes by targeting enos and redox signalling (2009) (0)
in cells autophagy: steady- state and real-time hyperpolarized (2019) (0)
Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma (2022) (0)
Ghrelin and its Analogues: Perspectives for a Story of Reverse Pharmacology (2004) (0)
Acute effects of a hallucinatory meal on subjective appetite and food intake: A randomized cross-over pilot trial (2019) (0)
METABOLIC AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CUSHING’S SYNDROME OF DIFFERENT ETIOLOGY BEFORE AND 1 YEAR AFTER DISEASE REMISSION (2010) (0)
A New Role for GPR103b in the Peripheral Regulation of Adipogenesis (2010) (0)
Metabolic and cardiovascular parameters in adult patients with Turner’s syndrome (2010) (0)
Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience (2019) (0)
First and second day cortisol levels as predictors of long-term hypocortisolism after pituitary surgery (2019) (0)
Long-Term Efficacy of Intensive Zoledronate Therapy and Predictors of Retreatment in Paget’s Disease of Bone (2021) (0)
High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial (2009) (0)
The GH releasing activity of ghrelin is insensitive to the negative growth hormone (GH) autofeedback in humans (2007) (0)
HYPOTHALAMO-PITUITARY-ADRENAL HYPERACTIVITY IN HUMAN AGING IS FURTHER ENHANCED BY MINERALCORTICOID ANTAGONISTS (2005) (0)
Analysis of cardiovascular comorbidities and events in a cohort of transgender people during GAHT (2022) (0)
Front & Back Matter (2013) (0)
Gender-affirming hormone treatment: friend or foe? Long term follow-up of 755 transgender and gender diverse people (2023) (0)
Effects of the ghrelin gene products on glucose metabolism in C2C12 muscle cells (2011) (0)
Session IV. Regulation of growth hormone and insulin-like growth factor I secretion : cholinergic enhancement potentiates growth hormone secretion by clonidine and L-dopa, but not arginine and galanin (1990) (0)
Wrist actigraphy detects sleep disorders in patients with Cushing's syndrome (2012) (0)
Simultaneous Measurement of Cortisol, Cortisone, Dexamethasone and Additional Exogenous Corticosteroids by Rapid and Sensitive LC–MS/MS Analysis (2022) (0)
EFFECTS OF GNRH-RECEPTOR BLOCKADE ON GONADAL AXIS IN WOMEN WITH FUNCTIONAL HYPOTHALAMIC AMENORRHEA (2007) (0)
Diagnostic and therapeutic aspects of GH deficiency (GHD) in the transition period (2002) (0)
Potential risk factors for post-treatment recurrence in patients with intermediate-risk differentiated thyroid carcinoma (2022) (0)
Impairment of GH secretion by ghrelin stimulation test in primary hyperparathyroidism (PHP) (2007) (0)
FRI0499 ACROMEGALY ARTROPATHY: IS THERE SOMETHING MORE BEHIND THE PAIN? A CROSS-SECTIONAL STUDY TO EVALUATE RHEUMATIC DISEASE IN GROWTH HORMONE SECRETING TUMOR PATIENTS (2020) (0)
The effects of the acute administration of alprazolam, a benzodiazepine, in patients with subclinical Cushing's syndrome (2012) (0)
Effects on glucose metabolism of high-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy (2010) (0)
Neuroendocrine function is altered in patients with chronic migraine and medication-overuse headache (2005) (0)
Does clinical status correlate with the severity of GH deficiency (GHD) in adults (1998) (0)
Thyrotoxicosis is coupled with quantitative and qualitative sleep disruptions (2006) (0)
ROLE OF AUTOPHAGY IN THE SURVIVAL EFFECT OF ACYLATED GHRELIN, UNACYLATED GHRELIN AND OBESTATIN IN HIT-15 AND INS1-E PANCREATIC β-CELLS (2009) (0)
Hormonal, metabolic and bone evaluation in a series of adrenal incidentalomas (2008) (0)
Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells (2017) (0)
Table of Contents (2011) (0)
QRFP43 and its fragment 26RFa both promote β-cell survival but differently regulate insulin secretion and glucose uptake in pancreatic β-cells and human pancreatic islets (2012) (0)
An observational retrospective study on the association of urine metanephrine levels with cardiometabolic risk in patients with nonfunctioning adrenal incidentaloma (2022) (0)
OR7,4 The somatotroph response to acylated ghrelin is refractory to the negative GH auto-feedback, but is sensitive to negative IGF-I feedback in man (2008) (0)
Copeptin assessment to predict vasoplegia after cardiopulmonary by-pass. An observational cohort study. (2020) (0)
Effect of ghrelin on anterior pituitary function in patients with anorexia nervosa (2002) (0)
The GH response to ghrelin in humans is impaired in conditions of hyper- and hypothyroidism (2006) (0)
EVALUATION OF BASAL AND STIMULATED ACTIVITY OF THE HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS WITH PRIMARY HYPERALDOSTERONISM (2003) (0)
Adult Clinical Case Sessions (2007) (0)
Impact of Surgery or Medical Treatment with the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients with Cushing Syndrome (2023) (0)
Role of GPR103b, a new G-protein coupled receptor, in the peripheral regulation of adipogenesis (2010) (0)
Mediated miR − 2 − SOD Unacylated Ghrelin Promotes Skeletal Muscle Regeneration Following Hindlimb Ischemia via Online (2013) (0)
Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy—A Narrative Review (2023) (0)
Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study (2023) (0)
WRIST ACTIGRAPHY REVEALS SLEEP DISTURBANCES IN PATIENTS WITH CUSHING’S DISEASE (2007) (0)
P-033. GH and IGF-I levels in catabolic patients with sepsis or trauma (1997) (0)
PPT1 COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY (2004) (0)
Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-[beta]-induced toxicity (2022) (0)
PATIENTS WITH AUTOIMMUNE DISEASES SHOW IMPAIRED ADRENAL SENSITIVITY TO ACTH 1-24 BUT ENHANCED BASAL AND STIMULATED CORTICOTROPH SECRETION (2004) (0)
Psychiatric disorders and anger in patients with controlled acromegaly. (2023) (0)
The cardiometabolic risk in patients with non-functioning adrenal incidentaloma: an observational, retrospective and propensity score matched study (2023) (0)
Subject Index Vol. 66, 1997 (1997) (0)
Welcome to 6th Annual European Meeting on the Management of Acromegaly (2015) (0)
Growth hormone deficiency in a case of septo-optic-dysplasia due to SOX2 mutation: should we re-test patients during the transition period? (2022) (0)
WRIST ACTIGRAPHY DOES NOT REVEAL SLEEP DISTURBANCES IN PATIENTS WITH ADDISON’S DISEASE UNDER CONVENTIONAL GLUCOCORTICOID REPLACEMENT THERAPY (2006) (0)
Obestatin inhibits high glucose-induced reactive oxygen species production and apoptosis in bovine aortic endothelial cells (2008) (0)
SIE, SIAMS, SIEDP, SIO, AIT, AME Informano (2011) (0)
A pharmaceutical composition for intranasal administration (1988) (0)
Effect of hexarelin on growth hormone secretion in Down syndrome (1996) (0)
Subject Index Vol. 4, 1993 (1993) (0)
Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in primates and mice (2012) (0)
Subject Index Vol. 63, 1996 (1996) (0)
Comprar Hormone Use And Abuse By Athletes | Ezio Ghigo | 9781441970138 | Springer (2010) (0)
Polycystic Ovary Syndrome - ReadingSample (2015) (0)
GLUCOCORTICOID RECEPTOR POLYMORPHISMS AND METABOLIC-CARDIOVASCULAR PROFILE IN PATIENTS WITH ADDISON’S DISEASE UNDER REPLACEMENT THERAPY (2011) (0)
Vasopressin and CTproAVP in pathogenetic conditions Diabetes insipidus (2014) (0)
Hypopituitarism is a Common Neuro-Endocrine Disease: How Manage to Inform the Medical Community (2006) (0)
Basal and stimulated GH secretion in active cushing's syndrome and 2 years after remission (2012) (0)
Motor Performance and Muscle Mass as a Function of Hormonal Responses to Exercise (2011) (0)
Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test (2022) (0)
Correction to: Pegvisomant in acromegaly: an update (2017) (0)
Comparison between cortisol’s and dexamethasone’s negative feedback action in humans:evidence for preferential sensitivity to the natural glucocorticoid (2013) (0)
The accuracy of adjusted unconventional indices for the assessment of selectivity and lateralization of adrenal vein sampling in the subtype diagnosis of primary aldosteronism (2022) (0)
EFFECT OF HEXARELIN, A SYNTHETIC GHRP, AND/OR hCRH ON ACTH- AND CORTISOL SECRETION IN NORMAL SUBJECTS AND IN PATIENTS WITH CUSHING’S SYNDROME (1997) (0)
Prognostic value of endocrine biomarkers in patients admitted to intensive care unit for COVID-19 (2022) (0)
Long-term pegvisomant treatment in acromegaly (2007) (0)
Dehydroepiandrosterone sulphate levels inpatients with hypopituitarism and severe growth hormone (GH) deficiency: Comparison with insulin-like growth factor I levels before and during GH replacement (1999) (0)
Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH–and GH-secreting pituitary neuroendocrine tumor (PitNETs) cell lines (2021) (0)
INTERACTION OF HYPOGLYCEMIA WITH PYRIDOSTIGMINE OR ARGININE ON GH SECRETION IN NORMAL SHORT CHILDREN (1995) (0)
Contents Vol. 76, 2002 (2002) (0)
Neuroendocrine effects of citalopram, a selective serotonine re-uptake inhibitor, during life span in humans / R. Berardelli; (0)
Physiological Roles of Des-Acyl Ghrelin (2012) (0)
EVALUATION OF BASAL AND STIMULATED HYPOTHALAMUS-PITUITARY-ADRENAL (HPA) ACTIVITY IN PRIMARY HYPERALDOSTERONISM (2004) (0)
T09-P-04 Efficacy of ED treatment with PDE5-inhibitors in the Italian real clinical practice contest: longitudinal data from the EDOS study (2008) (0)
The cut-off limits of GH response to GHRH + arginine test related to body mass index for the diagnosis of adult GH deficiency: do we need to review our diagnostic criteria? (2022) (0)
Use of growth hormone-releasing materials and their antagonists for treatment of tumors (1999) (0)
Shlomo Melmed: The Pituitary (2012) (0)
Long-term treatment with pegvisomant (Somavert®): Observations from 2090 acromegaly patients followed in ACROSTUDY (2017) (0)
Growth hormone releasing peptides/secretagogues (2007) (0)
Diabetogenic effects of a continuous infusion of acylated ghrelin in normal and type 2 diabetic patients (2008) (0)
T-28 Hypothalamic-pituitary-adrenal axis and adrenal dysfunction in non-septic cirrhotic patients with ascites: a pathophysiological and clinical evaluation (2013) (0)
Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines (2019) (0)
Ghrelin effects on spontaneous and stimulated LH secretion in human males (2007) (0)
Management of Growth Hormone Deficiency in Children Irradiated for Brain Tumours (2015) (0)
Growth Hormone, Growth Hormone Releasing Peptides (1998) (0)
Obestatin and ghrelin inhibit apoptosis of human pancreatic islet endothelial cells in high glucose culture (2010) (0)
Predictivity of ultrasonography (US) features in evaluation of malignancy in the solitary thyroid nodule. (2005) (0)
CHAPTER 26 – Hormones and Athletic Performance (2016) (0)
Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice. (2023) (0)
Erratum to: Shlomo Melmed: The Pituitary (2012) (0)
Secondary Diabetes: Clinical Considerations (2014) (0)
Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid Carcinoma (2023) (0)
Microalbuminuria as well as insulin sensitivity are improved under octreotide-lar treatment in acromegalic patients (2006) (0)
Single-run UHPLC-MS/MS method for simultaneous quantification of endogenous steroids and their phase II metabolites in serum for anti-doping purposes. (2022) (0)
Primary aldosteronism is very frequent in resistant hypertension and is associated to early renal vascular damage (2012) (0)
P-53 The pre-treatment with acylated ghrelin abolishes the GH response to GHRH and inhibits that to GHRH+ARGININE and ghrelin itself (2008) (0)
Energy status and glucocorticoid excess (2013) (0)
IGF-I response to short-term administration of low RHGH dose as function of sex, age and pathophysiological conditions (1998) (0)
GHRELIN AND SYNTHETIC GROWTH HORMONE SECRETAGOGUES: ENDOCRINE AND NON-ENDOCRINE ACTIONS (2002) (0)
GH but not IGF-I hypersecretion in acromegaly is generally attenuated in elderly acromegalics. (2002) (0)
How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients. (2023) (0)
SIE, SIAMS, SIEDP, SIO, AIT, AME Informano (2012) (0)
Treatment of acromegalic osteopathy in the real-life clinical practice: The baac (bone active drugs in acromegaly) multicenter study (2020) (0)
The Role of Neurotransmitters in Growth Hormone Secretion (1988) (0)
NON-acylated ghrelin AS A THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISEASES (2008) (0)
Surveillance study on the prevalence of manifestations, complications and illness associated to acromegaly (2012) (0)
Subject Index Vol. 76, 2002 (2002) (0)
Association between the circadian rhythm and the inhibitory effect of glucocorticoids on browning of adipocytes (2020) (0)
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study (2020) (0)
HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS SENSITIVITY TO THE NEGATIVE FEED-BACK ACTION OF CORTISOL IN HUMANS (2003) (0)
Erratum: Hypopituitarism following traumatic brain injury (TBI): A guideline Decalogue (Journal of Endocrinological Investigation (2004) 27, 8 (793)) (2005) (0)
Effects of mineralocorticoid agonists and antagonists on survival, proliferation and differentiation of adult rat hippocampal progenitor cells (2012) (0)
[Neuroregulation of GH secretion in aging]. (1993) (0)
Adrenocortical, somatotropic and antidiuretic response to nasal glucagon in healthy subjects. (2023) (0)
No feedback inhibition of obestatin during acylated ghrelin infusion in humans (2008) (0)
LETTER TO THE EDITORS (1986) (0)
Growth hormone deficiency in succesfully treated acromegalic patients is not protective from cardiac complications (2007) (0)
Ghrelin as new provocative test for the diagnosis of GH deficiency in adults (2009) (0)
Efficacy and safety of long-term treatment with pegvisomant in acromegaly: Italian pegvisomant observational study (ACROSTUDY) (2012) (0)
P9 Ghrelin test: a new tool for the diagnosis of GH deficiency in adults (2010) (0)
THE INHIBITORY EFFECT OF FLUDROCORTISONE ON HPA AXIS IS NOT ONLY EXERTED THROUGH HIPPOCAMPAL MR RECEPTORS: POSSIBLE CLINICAL IMPLICATIONS (2010) (0)
Growth hormone-releasing hormone (GHRH)induces cardioprotection in isolated heart akin to ischemic postconditioning (2010) (0)
The evaluation of metabolic effects following ghrelin and salbutamol administration (2009) (0)
Subject Index Vol. 71, Suppl. 1, 2009 (2009) (0)
L’ipopituitarismo post trauma cranico: dall’età pediatrica all’età adulta (2012) (0)
Effects of obestatin on proliferation and survival of adult rat hippocampal progenitor cells (2012) (0)
Combining GHRH/Arginine with a synacthen test diminishes the cortisol response (2006) (0)
Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy (2022) (0)
Sarcopenia in Endocrine Disorders – The Iceberg or Its Tip? (2015) (0)
Regulation of obestatin levels during unacylated ghrelin infusions in normal and type 2 diabetic patients (2009) (0)
MINERALCORTICOID RECEPTOR BLOCKADE ENHANCES THE ACTIVITY OF HYPOTHALAMUS-PITUITARY-ADRENAL AXIS IN HUMANS (2000) (0)
The story of a meeting (2008) (0)
FOLLOWING TREATMENT WITH DUAL-RELEASE HYDROCORTISONE IN PATIENTS WITH ADDISON ’ S DISEASE (2016) (0)
Time dependency of somatotroph dysfunction following radiation damage of the hypothalamic-pituitary axis (2002) (0)
ACTIVITY OF GH/IGF‐I AXIS IN CATABOLIC PATIENTS WITH SEPSIS OR TRAUMA: 617 (1997) (0)
Obestatin promotes glut-4 translocation and glucose uptake in 3T3-L1 adipocytes and inhibits lipolysis in 3T3-L1 and human visceral and subcutaneous adipocytes (2009) (0)
Front & Back Matter (2014) (0)
Conventional glucocorticoid replacement therapy in patients with Addisons disease: effects on metabolic and bone parameters (2007) (0)
Subject Index Vol. 68, Suppl. 5, 2007 (2007) (0)
LB02.08: PREDICTORS OF RECURRENCE OF PHEOCHROMOCYTOMAS/PARAGANGLIOMAS PRELIMINARY DATA FROM A RETROSPECTIVE MULTICENTER STUDY IN PIEDMONT (2015) (0)
GHRELIN IN HUMANS (2012) (0)
The GH response to ghrelin in humans is reduced in conditions of hyper- and hypothyroidism (2006) (0)
Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials (2018) (0)
Glucocorticoids enhance browning and thermogenic functions of mouse and human white adipocytes (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ezio Ghigo?

Ezio Ghigo is affiliated with the following schools: